Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 2/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | DBH | P09172 | 1/20 | 0.50 |
| ▸ | RECQL | P46063 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 4/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | CHRNA1 | P02708 | 2/20 | 0.39 |
| ▸ | CHRNG | P07510 | 2/20 | 0.39 |
| ▸ | CHRNB1 | P11230 | 2/20 | 0.39 |
| ▸ | CHRNB2 | P17787 | 2/20 | 0.39 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.39 |
| ▸ | CHRNB4 | P30926 | 2/20 | 0.39 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.39 |
| ▸ | CHRNA3 | P32297 | 2/20 | 0.39 |
| ▸ | CHRNA4 | P43681 | 2/20 | 0.39 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.39 |
| ▸ | CHRND | Q07001 | 2/20 | 0.39 |
| ▸ | HCAR3 | P49019 | 1/20 | 0.38 |
| ▸ | ESR1 | P03372 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15075229 | 0.79 | MAPT (0.47) | GAAKDM4EMAPTMAPK1HCAR3 | |
| SCHEMBL2120103 | 0.79 | HCAR3 (0.57) | GAAKDM4EMAPTMAPK1HCAR3 | |
| SCHEMBL3670046 | 0.79 | KDM4E (0.59) | GAAKDM4EDBHRECQLMAPT | |
| SCHEMBL3117262 | 0.78 | GAA (0.50) | GAAKDM4EMAPTMAPK1HCAR3 | |
| SCHEMBL172415 | 0.76 | KDM4E (0.71) | GAAKDM4EDBHRECQLMAPT | |
| SCHEMBL2237695 | 0.74 | GAA (0.53) | GAAKDM4EDBHRECQLMAPT | |
| SCHEMBL12780290 | 0.74 | GAA (0.53) | GAAKDM4EDBHRECQLCHRNA1 | |
| SCHEMBL879752 | 0.74 | CHRNA1 (0.64) | GAAKDM4EDBHRECQLMAPT | |
| SCHEMBL10355547 | 0.74 | NPC1 (0.58) | GAAKDM4EMAPTMAPK1HPGD | |
| SCHEMBL10473157 | 0.73 | KMT2A (0.42) | GAAMAPTMAPK1HCAR3ESR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210228727-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF VIRAL INFECTIONS | CIDARA THERAPEUTICS, INC. (US) | 2021-07-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210228727-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF VIRAL INFECTIONS | FCGR3B, ALB, FCGR1A | GAA 159/4885KDM4E 4753/4885DBH 3618/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.